Amneal announces acquisition of 65.1% majority interest of generics distributing company, AvKARE, boosting its presence in the generics and federal healthcare market.
US FTC rules that Endo used its dominant position in the market to delay competition from Impax with an illegal pay-for-delay deal for its Opana ER product.
